Al-Lehebi, Riyad Omar
Al Ahmad, Mona
Maturu, Venkata Nagarjuna
Mesa, Alejandra Galeano
Mahboub, Bassam
Garcia, Elizabeth
Fernandez, Patricia
Soares, Claudia
Abreu, Gabriela
dos Santos, Debora
Queiroz, Juliana
Raimondi, Alejandro
Laucho-Contreras, Maria
Noibi, Saeed
Levy, Gur
Bavbek, Sevim http://orcid.org/0000-0002-7884-0830
Funding for this research was provided by:
GSK
Article History
Received: 17 July 2024
Accepted: 7 August 2024
First Online: 31 August 2024
Declarations
:
: Riyad Omar Al-Lehebi has given lectures at meetings supported by AstraZeneca, Boehringer Ingelheim, GSK and Sanofi, and received advisory board fees from GSK. Mona Al Ahmad received lecture and advisory board honoraria from Sanofi, GSK and AstraZeneca. Venkata Nagarjuna Maturu has given lectures at meetings supported by AstraZeneca, GSK, Novartis, Sun Pharma, Cipla and Lupin, and participated in advisory boards with AstraZeneca and GSK. Alejandra Galeano Mesa has no conflicts of interest to report. Bassam Mahboub is a speaker for AstraZeneca, GSK and Sanofi. Elizabeth Garcia reports having been a speaker for Sanofi, Novartis, and Pfizer and received advisory board fees from GSK, Sanofi and Novartis. Patricia Fernandez reports having been a speaker for AstraZeneca, GSK, Sanofi and Teva, and participated in advisory boards with AstraZeneca, GSK and Sanofi. Claudia Soares, Alejandro Raimondi, Maria Laucho-Contreras, Saeed Noibi and Gur Levy are employed by GSK and hold financial equities in GSK. Gabriela Abreu and Juliana Queiroz are complementary employees of GSK and do not hold financial equities in GSK. Debora dos Santos was a complementary worker of GSK at the time of the study analysis. Debora dos Santos’ current affiliation is a postdoctoral fellowship at University of Brasilia under the Program of Collective Health. Sevim Bavbek has given lectures at meetings supported by AstraZeneca, GSK and Novartis, and reports receipt of advisory board fees from AstraZeneca, GSK and Novartis.
: The study protocol was reviewed and approved by the respective institutional review boards and ethics committees of the participating countries and the study was conducted in accordance with the International Conference on Harmonization, Good Pharmacoepidemiology Practice, Good Clinical Practice and all applicable patient privacy requirements and country-specific requirements relevant for an observational study.